Trial Profile
Randomized phase II trial with infliximab (Remicade) in patients with myelodysplastic syndromes and a relatively low risk of developing acute leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 18 Nov 2011 Interim results published in Haematologica.
- 18 Dec 2006 Status change
- 13 Oct 2006 New trial record.